An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties
Statistics in Medicine · 2025
DOI: 10.1002/sim.70180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Ying Cui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Data Science, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Models, Statistical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
In clinical trials, multiple outcomes of different priorities commonly occur as the patient's response may not be adequately characterized by a single outcome. Win statistics are appealing summary measures for between‐group difference at more than one endpoint. When defining the result of pairwise comparisons of a time‐to‐event endpoint, it is desirable to allow ties to account for incomplete follow‐up and not clinically meaningful difference in endpoints of interest. In this article, we propose a class of win statistics for time‐to‐event endpoints with a user‐specified equivalence margin. These win statistics are identifiable in the presence of right censoring and do not depend on the censoring distribution. We then develop estimation and inference procedures for the proposed win statistics based on inverse‐probability‐of‐censoring weighting adjustment to handle right censoring. We conduct extensive simulations to investigate the operational characteristics of the proposed procedure in the finite sample setting. A real oncology trial is used to illustrate the proposed approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
- Pfizer Research & Development, Pfizer Inc., New York, New York, USA.
- Sarepta Therapeutics Inc., Cambridge, Massachusetts, USA.
- Department of Industrial Engineering and Economics, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Ying Cui, Bo Huang, Ryuji Uozumi, Lu Tian
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Cui, Y., Huang, B., Dong, G., Uozumi, R., & Tian, L. (2025). An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties. Statistics in Medicine. https://doi.org/10.1002/sim.70180
Vancouver
Cui Y, Huang B, Dong G, Uozumi R, Tian L. An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties. Statistics in Medicine. 2025. doi:10.1002/sim.70180
BibTeX
@article{Cui2025,
author = {Cui, Ying and Huang, Bo and Dong, Gaohong and Uozumi, Ryuji and Tian, Lu},
title = {An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70180}
}
EUVIMED